Provectus Biopharmaceuticals Inc (PVCT)

[Mokyo Toe]

It is mind-numbingly confusing, because both the price and the number of shares fluctuates. The .053 is an old guesstimate I use for shorthand; it may be in the 4's now because of our average 60 day share price. Depending on where the price was reset, the number of new shares can rise or fall. The ultimate maximum is 240,000,000 shares, but could wind up being much fewer; it depends where they get exercised.

This has already been priced into the pps, which was at .27 (after a long fade from around .85) when this was announced. After it was announced, PVCT crashed down to .13, on its way to .01

What effect this will have on trading though is a mystery to me. I can't figure out how to do the math on this. Maybe you will have better luck?

This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Provectus Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), that Maxim shall serve as the placement agent for the Company, on a best efforts basis, in connection with the proposed placement (the “Placement”) of an aggregate of up to 240,000 shares of (the “Shares”) of the Company’s Series B Convertible Preferred Stock, par value $0.001 per share, which Shares shall be initially convertible into an aggregate of up to 240,000,000 shares of the Company’s common stock, par value $0.001 per share (“Common Stock”) (subject to adjustment as provided in the Certificate of Designation (as defined below)), and warrants initially exercisable to purchase an aggregate of up to 24,000,000 shares of Common Stock (subject to adjustment as provided therein) (each a “Warrant” and collectively, the “Warrants”). The Shares, the Warrants and the shares of Common Stock underlying the Shares (the “Conversion Shares”) and underlying the Warrants (the “Warrant Shares”) are hereinafter referred to collectively as the “Securities.” The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that Maxim would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete the Placement. This Agreement and the documents executed and delivered by the Company and the Purchasers in connection with the Placement, including but not limited to the Purchase Agreement (as defined below), the Certificate of Designation and the Warrants, shall be collectively referred to herein as the “Transaction Documents.” The date of the closing of the Placement shall be referred to herein as the “Closing Date.” The Company expressly acknowledges and agrees that Maxim’s obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by Maxim to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Maxim with respect to securing any other financing on behalf of the Company. The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Placement. The sale of the Securities to each Purchaser will be evidenced by that certain Securities Purchase Agreement, dated as of August 25, 2016 (the “Purchase Agreement”), between the Company and each Purchaser in a form reasonably acceptable to the Company and Maxim. Capitalized terms that are not otherwise defined herein have the meanings given to such terms in the Purchase Agreement. Prior to the signing of any Purchase Agreement, officers of the Company will be available to answer inquiries from prospective Purchasers.

Here is the 8-K about it:

http://irdirect.net/filings/viewer/index/315545/000119312516691914/